Hydrinity expands to France to meet medical-grade skin care demand
Key takeaways
- Hydrinity partners with VeraSeaCosmetics to expand into the French market.
- The French skin care market is projected to grow significantly, driven by demand for medical-grade products.
- Hydrinity’s retinal technology reveals improved results and no irritation.

Hydrinity Accelerated Skin Science has begun a strategic partnership with VeraSeaCosmetics of France. The partnership will leverage over 5,100 plastic surgeons and dermatologists, alongside 39,000 general practitioners (GPs) specializing in cosmetic solutions.
The provider of medical and aesthetic products in the French market, VeraSeaCosmetics, says that cosmetic specialist GPs are a growing segment for the beauty industry. Meanwhile, Hydrinity touts to be the “fastest-growing professional skin care brand in the US.” According to the brand, France has over 26 million skin care consumers.
The French skin care market is projected to grow to over US$5.4 billion by the end of 2025, with facial products constituting the largest segment at over US$1.2 billion. The expansion also comes as French consumers increasingly prioritize health, wellness, and high-performance skin care.
Hydrinity says technological innovation remains a primary driver of growth in the professional skin care sector. The skin care brand reports that France ranks as the eighth-largest skin care market globally, following Germany and Russia, and that its consumers demonstrate strong interest in advanced, natural, and “green” formulations.
The collaborators also postulate that additional drivers of their partnership’s success include rising quality-of-life expectations, the positive impact of skin care on self-esteem and social engagement, and a continued shift toward premium and luxury brands.
“VeraSeaCosmetics is a leading medical technology provider with over two decades of expertise in the French market. Their commitment to delivering exceptional service, education, and training will help position Hydrinity as a premier skin care solution for top medical aesthetic providers across France,” said Brent Nixon, COO of Hydrinity.
France’s skin care demand
Hydrinity brings advanced skin care to France.
Hydrinity says that growth in the male grooming segment, heightened consumer awareness, and the introduction of innovative products tailored to a variety of clinical and skin type needs are accelerating market expansion in France.
The brand adds that demand for natural and organic solutions continues to rise, supported by France’s longstanding cultural emphasis on personal care and refinement. The drive for sustainable cosmetics in the market is also modernly influenced by social media and beauty opinion leaders.
“We have been searching for the most advanced skin care technologies and companies for some time now for our market. When we were introduced to Hydrinity and evaluated by physician thought leaders, it became clear the brand is truly extraordinary,” says Véronique Lencznar, Founder and CEO of VeraSeaCosmetics.
Retinal results
Coinciding with the partnership, Hydrinity has published a clinical study demonstrating that its retinal, encapsulated in biomimetic exosomes, significantly improved the appearance of photodamaged skin, with no product-related irritation.
The 12-week clinical study published in the Journal of Cosmetic Dermatology evaluated 20 women aged 35–65 with mild-to-moderate photodamage. They applied Hydrinity RetaXome Daily Retinal Hydrator nightly, demonstrating progressive improvement at each evaluation point through week 12.
Participants’ redness decreased at each follow-up visit, with the mean erythema improving by 68% at week 12 compared with baseline. Skin tone evened out at the earliest by week 2, with an overall improvement of 56% by week 12.
The study’s subjects also reported progressive improvement in skin texture and an overall 63% improvement from baseline by week 12. Meanwhile, fine lines and wrinkles were reduced at all follow-up visits, with a 36% improvement at week 12.
Hydrinity has released study results for its retinal.
Almost all (95%) of participants were satisfied and would recommend the product. No product-related adverse events were reported throughout the 12-week study.
“Retinal has long been recognized as one of the most effective ingredients for photoaged skin — but tolerability has remained its greatest limitation,” says Dr. Michael Gold, MD, FAAD, lead investigator and board-certified dermatologist.
“What’s remarkable about this study is that we achieved the hallmark benefits of retinal — improved tone, smoother texture, reduced wrinkles — without the typical dryness, flaking, or irritation. The biomimetic exosome delivery system fundamentally changes the way we approach retinoid therapy.”
Hydrinity’s innovation is driven by an engineered biomimetic exosome platform that encapsulates retinal for precise, controlled release, and enhanced penetration. Combined with the brand’s proprietary Supercharged Hyaluronic Acid and plant-derived antioxidant and anti-inflammatory actives, the formulation is said to enhance results while supporting skin barrier integrity.
“This study marks an important milestone in the Hydrinity mission to fuse biotechnology with advanced skin care,” says Keith O’Briant, CEO of Hydrinity.










